[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"BostonGene\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":78},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100537056","bostongene-and-exigent-genomic-insight-study-100537056",false,"NCT06272864","BostonGene and Exigent Genomic INsight Study","BostonGene and Exigent Genomic INsight (BEGIN) Study: A Prospective Study of Comprehensive Molecular Testing in Advanced Cancer Patients in the Community Setting","BEGIN","Inclusion Criteria:\n\n* Patients must have a confirmed malignancy of:\n\nLocally recurrent, unresectable, or metastatic breast cancer or; Unresectable stage III or metastatic non-small cell lung cancer or; Unresectable or metastatic melanoma or; Locally advanced or metastatic l sarcoma.\n\n* Life expectancy \\> 3 months as per the treating physician\n* Willingness to provide informed consent\n* Living in the United States at time of enrollment\n* Agree to participate in genomic and molecular profiling\n\nExclusion Criteria:\n\n* not meeting the inclusion criteria","ALL","18 Years",{"count":20,"type":21},400,"ESTIMATED","2 Years","OBSERVATIONAL","The BEGIN Study by BostonGene and Exigent Genomic INsight evaluates the efficacy of comprehensive molecular testing in advanced cancer patients. Using the BostonGene Tumor Portrait test, the study aims to identify actionable findings, assess feasibility, and determine patient enrollment in clinical trials. Four cohorts of 100 patients each will be studied over two years, focusing on treatment decisions and patient outcomes. This study seeks to demonstrate the clinical utility of genomic testing in guiding therapy for advanced cancer patients in community settings.",[26,27,28,29],"Breast Cancer","Non-small Cell Lung Cancer","Melanoma","Sarcoma",[31,32,33,34],"Comprehensive Molecular Testing","BostonGene Tumor Portrait Test","Molecularly Matched Therapy","DNA and RNA Targets","RECRUITING","2025-02-14",{"date":38,"type":39},"2025-02-17","ACTUAL",{"date":41,"type":39},"2024-04-08",{"date":43,"type":21},"2028-01-08",{"name":45,"class":46},"BostonGene","INDUSTRY",7,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100438641","bostongene-integrated-genomic-registry-bigr-100438641","NCT04991922","BostonGene-Integrated Genomic Registry (BIGR)","BostonGene-Integrated Genomic Registry Study","Inclusion Criteria:\n\n1. Suspected or confirmed malignancy\n2. Planned comprehensive genomic (\\> 100 genes) and\u002For molecular analysis; or genomic and\u002For molecular data available from prior sequencing\n3. Baseline demographics and treatment information available\n4. Willingness for future contact by BIRG study personnel to provide information regarding associated cancer outcomes and treatment.\n5. Signed informed consent to participate in the study.\n6. Living in the United States at the time of enrollment\n\nExclusion Criteria:\n\nLife expectancy \\\u003C 3 months",{"count":56,"type":21},100000,"The purpose of this project is to develop a comprehensive database of genomic, transcriptomic, molecular, and clinical characteristics of oncology patients to discover, define, and develop genomic and transcriptomic markers to improve future clinical outcomes across cancer types",[59],"Malignancy",[61,62,63,64,65,66,67,68],"cancer","precision medicine","WES","RNA-seq","immuno-therapy","genomic","transcriptomic","multiomic","2024-02-06",{"date":71,"type":39},"2024-02-07",{"date":73,"type":39},"2021-07-01",{"date":75,"type":21},"2036-07-01",{"name":45,"class":46},1,""]